Overview

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Status:
Not yet recruiting
Trial end date:
2026-06-26
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company